Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHINOOK THERAPEUTICS, INC.ADRO · Entity 110632 | Chief Scientific Officer | August 10, 2017 | August 11, 2017 |
| HTG MOLECULAR DIAGNOSTICS, INCHTGM · Entity 112530 | Director | August 18, 2022 | August 22, 2022 |
| Tempest Therapeutics, Inc.TPST · Entity 7734 | Director · President | January 03, 2023 | January 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHINOOK THERAPEUTICS, INC.
Report date August 10, 2017 · Filed August 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,900 |
Ending reported balance
After 2017-08-11 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2017-08-10 · Exercise / conversion · Acquired 40,912 · Balance 80,812 Row 2 · 2017-08-10 · Sale · Disposed 40,912 · Balance 39,900 F1: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2017. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.10 to $12.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 3 · 2017-08-11 · Exercise / conversion · Acquired 9,088 · Balance 48,988 Row 4 · 2017-08-11 · Sale · Disposed 9,088 · Balance 39,900 F1: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2017. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.10 to $11.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2024-07-30 | Direct | 135,416 |
Reported balance
After 2017-08-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-08-10 · Exercise / conversion · Disposed 40,912 · Balance 135,416 F4: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of July 31, 2014. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2024-07-30 | Direct | 126,328 |
Reported balance
After 2017-08-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-08-11 · Exercise / conversion · Disposed 9,088 · Balance 126,328 F4: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of July 31, 2014. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2017.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.10 to $12.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.10 to $11.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of July 31, 2014.
HTG MOLECULAR DIAGNOSTICS, INC
Report date August 18, 2022 · Filed August 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.94 · Expires 2032-08-17 | Direct | 8,000 |
Reported balance
After 2022-08-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-18 · Grant · Acquired 8,000 · Balance 8,000 F1: One-third of the shares will vest twelve months after August 18, 2022 and the remaining shares will vest monthly in equal installments over a two year period such that the stock option is fully vested on the third anniversary of August 18, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third of the shares will vest twelve months after August 18, 2022 and the remaining shares will vest monthly in equal installments over a two year period such that the stock option is fully vested on the third anniversary of August 18, 2022.
Tempest Therapeutics, Inc.
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2033-01-02 | Direct | 102,700 |
Reported balance
After 2023-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 102,700 · Balance 102,700 F1: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2023 Filed Jan 5, 2023 20:01 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 102,700 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-23-002146 · doc4.xml · derivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,700 Underlying: Common Stock · 102,700 shares Expires 2033-01-02 F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 17:27 UTC | HTG MOLECULAR DIAGNOSTICS, INC HTGM · Entity 112530 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001209191-22-047052 · doc4.xml · derivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2032-08-17 F1 · derivative.exercise_date: One-third of the shares will vest twelve months after August 18, 2022 and the remaining shares will vest monthly in equal installments over a two year period such that the stock option is fully vested on the third anniversary of August 18, 2022. Read SEC document |
| June 21, 2022 Filed Jun 22, 2022 16:31 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 87,801 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001179110-22-003399 · edgar.xml · derivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,801 Underlying: Common Stock · 87,801 shares Expires 2032-06-20 F1 · derivative.exercise_date: Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 18:36 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | PurchaseCommon Stock | 2,000 | $4.78 | $9,560.00 |
DisclosureSEC source: 0001209191-22-002963 · doc4.xml · nonDerivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,343 Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 19:22 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 53,100 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001209191-22-002245 · doc4.xml · derivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,100 Underlying: Common Stock · 53,100 shares Expires 2032-01-03 F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 4, 2022, subject to the reporting person's continued service. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:55 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 1,000,000 | Not disclosed Strike: $26.40 | Not disclosed |
DisclosureSEC source: 0001140361-21-022784 · form4.xml · derivative · entry 5 Dubensky Thomas W. · CIK 0001635590 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2031-04-28 F1 · price: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc." F5 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of Closing, June 25, 2021, subject to the reporting person's continued service. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:55 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 8,050 | Not disclosed Strike: $10.25 | Not disclosed |
DisclosureSEC source: 0001140361-21-022784 · form4.xml · derivative · entry 4 Dubensky Thomas W. · CIK 0001635590 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,050 Underlying: Common Stock · 8,050 shares Expires 2031-03-09 F1 · price: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc." F4 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of March 5, 2021, subject to the reporting person's continued service. Notwithstanding the foregoing, if, within three months prior to or 12 months following a change in control, the Issuer terminates the reporting person's employment without cause or the reporting person resigns for good reasons, then the vesting of all of the shares subject to this option will be immediately accelerated such that all shares subject to the option will be deemed fully vested and exercisable as of the reporting person's last day of employment, provided that the reporting person satisfies certain severance conditions. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:55 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 45,988 | Not disclosed Strike: $5.90 | Not disclosed |
DisclosureSEC source: 0001140361-21-022784 · form4.xml · derivative · entry 3 Dubensky Thomas W. · CIK 0001635590 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,988 Underlying: Common Stock · 45,988 shares Expires 2030-03-29 F1 · price: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc." F3 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of February 20, 2020, subject to the reporting person's continued service. Notwithstanding the foregoing, if, within three months prior to or 12 months following a change in control, the Issuer terminates the reporting person's employment without cause or the reporting person resigns for good reasons, then the vesting of all of the shares subject to this option will be immediately accelerated such that all shares subject to the option will be deemed fully vested and exercisable as of the reporting person's last day of employment, provided that the reporting person satisfies certain severance conditions. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:55 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 36,263 | Not disclosed Strike: $4.97 | Not disclosed |
DisclosureSEC source: 0001140361-21-022784 · form4.xml · derivative · entry 2 Dubensky Thomas W. · CIK 0001635590 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,263 Underlying: Common Stock · 36,263 shares Expires 2028-10-02 F1 · price: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc." F2 · derivative.exercise_date: All of the shares underlying this option vest upon Closing. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:55 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantCommon Stock | 111,343 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-022784 · form4.xml · nonDerivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,343 F1 · price: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc." Read SEC document |
| August 11, 2017 Filed Aug 11, 2017 20:03 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,088 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001209191-17-048673 · doc4.xml · derivative · entry 6 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,328 Underlying: Common Stock · 9,088 shares Expires 2024-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of July 31, 2014. Read SEC document |
| August 11, 2017 Filed Aug 11, 2017 20:03 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 9,088 | $11.17 | $101,538.41 |
DisclosureSEC source: 0001209191-17-048673 · doc4.xml · nonDerivative · entry 4 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.10 to $11.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 11, 2017 Filed Aug 11, 2017 20:03 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 9,088 | $1.00 | $9,088.00 |
DisclosureSEC source: 0001209191-17-048673 · doc4.xml · nonDerivative · entry 3 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 20:03 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,912 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001209191-17-048673 · doc4.xml · derivative · entry 5 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,416 Underlying: Common Stock · 40,912 shares Expires 2024-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of July 31, 2014. Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 20:03 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 40,912 | $11.43 | $467,665.07 |
DisclosureSEC source: 0001209191-17-048673 · doc4.xml · nonDerivative · entry 2 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.10 to $12.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 20:03 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 40,912 | $1.00 | $40,912.00 |
DisclosureSEC source: 0001209191-17-048673 · doc4.xml · nonDerivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2017 Filed Jul 6, 2017 19:10 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,512 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-17-044232 · doc4.xml · derivative · entry 9 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,571 Underlying: Common Stock · 4,512 shares Expires 2021-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the Option were fully vested as of September 1, 2015. Read SEC document |
| July 06, 2017 Filed Jul 6, 2017 19:10 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 4,512 | $11.23 | $50,673.37 |
DisclosureSEC source: 0001209191-17-044232 · doc4.xml · nonDerivative · entry 6 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.10 to $11.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 06, 2017 Filed Jul 6, 2017 19:10 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 4,512 | $0.52 | $2,346.24 |
DisclosureSEC source: 0001209191-17-044232 · doc4.xml · nonDerivative · entry 5 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 19:10 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 33,688 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-17-044232 · doc4.xml · derivative · entry 8 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,083 Underlying: Common Stock · 33,688 shares Expires 2021-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the Option were fully vested as of September 1, 2015. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 19:10 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 33,688 | $11.46 | $385,936.47 |
DisclosureSEC source: 0001209191-17-044232 · doc4.xml · nonDerivative · entry 4 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.90 to $11.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 19:10 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 33,688 | $0.52 | $17,517.76 |
DisclosureSEC source: 0001209191-17-044232 · doc4.xml · nonDerivative · entry 3 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 19:10 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,800 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-17-044232 · doc4.xml · derivative · entry 7 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,771 Underlying: Common Stock · 11,800 shares Expires 2021-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the Option were fully vested as of September 1, 2015. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 19:10 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 11,800 | $11.02 | $130,027.74 |
DisclosureSEC source: 0001209191-17-044232 · doc4.xml · nonDerivative · entry 2 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.80 to $11.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 19:10 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 11,800 | $0.52 | $6,136.00 |
DisclosureSEC source: 0001209191-17-044232 · doc4.xml · nonDerivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 21:06 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (right to buy) · Derivative | 32,625 | $0.00 Strike: $10.75 | $0.00 |
DisclosureSEC source: 0001209191-17-039997 · doc4.xml · derivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,625 Underlying: Common Stock · 32,625 shares Expires 2027-06-11 F1 · derivative.exercise_date: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of June 12, 2017. Read SEC document |
| June 05, 2017 Filed Jun 5, 2017 19:25 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 17,577 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-17-037970 · doc4.xml · derivative · entry 9 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,571 Underlying: Common Stock · 17,577 shares Expires 2021-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the Option were fully vested as of September 1, 2015. Read SEC document |
| June 05, 2017 Filed Jun 5, 2017 19:25 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 17,577 | $9.99 | $175,627.63 |
DisclosureSEC source: 0001209191-17-037970 · doc4.xml · nonDerivative · entry 6 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.90 to $10.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 05, 2017 Filed Jun 5, 2017 19:25 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 17,577 | $0.52 | $9,140.04 |
DisclosureSEC source: 0001209191-17-037970 · doc4.xml · nonDerivative · entry 5 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 19:25 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 48,753 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-17-037970 · doc4.xml · derivative · entry 8 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,148 Underlying: Common Stock · 48,753 shares Expires 2021-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the Option were fully vested as of September 1, 2015. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 19:25 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 48,753 | $10.10 | $492,283.42 |
DisclosureSEC source: 0001209191-17-037970 · doc4.xml · nonDerivative · entry 4 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.90 to $10.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 19:25 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 48,753 | $0.52 | $25,351.56 |
DisclosureSEC source: 0001209191-17-037970 · doc4.xml · nonDerivative · entry 3 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 19:25 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 77,971 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-17-037970 · doc4.xml · derivative · entry 7 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,901 Underlying: Common Stock · 77,971 shares Expires 2021-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the Option were fully vested as of September 1, 2015. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 19:25 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 77,971 | $10.00 | $779,865.94 |
DisclosureSEC source: 0001209191-17-037970 · doc4.xml · nonDerivative · entry 2 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.90 to $10.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 19:25 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 77,971 | $0.52 | $40,544.92 |
DisclosureSEC source: 0001209191-17-037970 · doc4.xml · nonDerivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2017 Filed May 15, 2017 18:56 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,299 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-17-032488 · doc4.xml · derivative · entry 6 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,872 Underlying: Common Stock · 4,299 shares Expires 2021-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the Option were fully vested as of September 1, 2015. Read SEC document |
| May 12, 2017 Filed May 15, 2017 18:56 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 4,299 | $9.92 | $42,657.69 |
DisclosureSEC source: 0001209191-17-032488 · doc4.xml · nonDerivative · entry 4 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.90 to $9.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 12, 2017 Filed May 15, 2017 18:56 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 4,299 | $0.52 | $2,235.48 |
DisclosureSEC source: 0001209191-17-032488 · doc4.xml · nonDerivative · entry 3 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2017 Filed May 15, 2017 18:56 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,400 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-17-032488 · doc4.xml · derivative · entry 5 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,171 Underlying: Common Stock · 1,400 shares Expires 2021-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the Option were fully vested as of September 1, 2015. Read SEC document |
| May 11, 2017 Filed May 15, 2017 18:56 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 1,400 | $9.91 | $13,869.94 |
DisclosureSEC source: 0001209191-17-032488 · doc4.xml · nonDerivative · entry 2 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.90 to $9.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 11, 2017 Filed May 15, 2017 18:56 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 1,400 | $0.52 | $728.00 |
DisclosureSEC source: 0001209191-17-032488 · doc4.xml · nonDerivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 20:04 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,931 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001209191-17-019990 · doc4.xml · derivative · entry 7 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,289 Underlying: Common Stock · 6,931 shares Expires 2025-01-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of January 10, 2015. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 20:04 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,165 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-17-019990 · doc4.xml · derivative · entry 6 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,571 Underlying: Common Stock · 3,165 shares Expires 2021-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the Option were fully vested as of September 1, 2015. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 20:04 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 14,904 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-17-019990 · doc4.xml · derivative · entry 5 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,491 Underlying: Common Stock · 14,904 shares Expires 2021-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the Option were fully vested as of December 31, 2015. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 20:04 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 25,000 | $10.96 | $274,077.50 |
DisclosureSEC source: 0001209191-17-019990 · doc4.xml · nonDerivative · entry 4 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.75 to $11.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 20:04 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 6,931 | $1.45 | $10,049.95 |
DisclosureSEC source: 0001209191-17-019990 · doc4.xml · nonDerivative · entry 3 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 20:04 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 3,165 | $0.52 | $1,645.80 |
DisclosureSEC source: 0001209191-17-019990 · doc4.xml · nonDerivative · entry 2 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 20:04 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 14,904 | $0.52 | $7,750.08 |
DisclosureSEC source: 0001209191-17-019990 · doc4.xml · nonDerivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 17:15 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-17-002230 · doc4.xml · derivative · entry 3 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,422 Underlying: Common Stock · 25,000 shares Expires 2021-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the Option were fully vested as of December 31, 2015. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 17:15 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 25,000 | $11.16 | $278,990.00 |
DisclosureSEC source: 0001209191-17-002230 · doc4.xml · nonDerivative · entry 2 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.95 to $11.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.